Based on research at Institute for Cancer Research, Nuvectis Pharma is working on precision medicines for cancer.
Nuvectis, a US-based biopharmaceutical company focused on oncology based on research at University of London’s Institute of Cancer Research (ICR), has completed a $15m series A round backed by undisclosed institutional and private investors.
Nuvectis is working on precision medicines for serious conditions of unmet medical need in oncology.
It has licensed NXP800, an oral small molecule inhibitor of the heat shock factor 1 (HSF1) pathway, from the CRT Pioneer Fund. In preclinical studies, NXP800 has inhibited tumour…
